Orforglipron

Overview

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist currently in Phase 3 clinical trials for obesity and type 2 diabetes. Unlike peptide GLP-1 agonists, it is a structurally distinct oral compound designed natively for oral bioavailability without requiring absorption-enhancing technology.

Research Context

Phase 2 data for Orforglipron published in 2023 demonstrated weight reductions of up to 14.7% over 36 weeks in adults with obesity — comparable to early semaglutide data — with a well-characterised tolerability profile. As a non-peptide small molecule, it offers intrinsic oral bioavailability without the formulation challenges of peptide-based GLP-1 agonists. Research interest is concentrated on its potential as a once-daily oral alternative to injectable GLP-1 therapies, with implications for accessibility, patient adherence, and global use in metabolic disease. It represents the leading non-peptide GLP-1 agonist in late-stage development. Mechanistic studies continue to characterise its receptor binding profile and downstream signalling relative to peptide analogs.

Oral Capsule Format

Orforglipron is intrinsically oral — its small-molecule structure confers native gastrointestinal stability and absorption that peptide GLP-1 agonists require engineered solutions to achieve. Biohacker supplies it in a precisely dosed capsule format at research-grade purity with full lot documentation.

36mg per capsule  ·  60 capsules per bottle. Every batch independently tested for purity, mass confirmation, and endotoxin compliance. Certificate of Analysis available for each lot.

For research purposes only. Not for human or veterinary use.